Search
J147
go.drugbank.com/drugs/DB13957Experimental[A31606,A31607,A31608] It is a curcumin derivative and a potent neurogenic and neuroprotective drug candidate initially developed for the treatment of neurodegenerative conditions associated with aging
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesPiperaquine
go.drugbank.com/drugs/DB13941ApprovedInvestigationalEurartesim was first authorized for market by the European Medicines Agency in October 2011.
Phenolphthalein
go.drugbank.com/drugs/DB04824ApprovedWithdrawnPhenolphthalein was withdrawn in Canada due to concerns with carcinogenicity in 1997.
Categories: Drugs for ConstipationLunsotogene parvec
go.drugbank.com/drugs/DB18278ApprovedInvestigationalLunsotogene parvec is a first-in-class dual adeno-associated virus serotype 1 vector-based gene therapy developed to address an unmet medical need for OTOF-related sensorineural hearing loss. … [L56136] On April 23, 2026, the FDA granted accelerated approval for the treatment of pediatric and adult patients with severe-to-profound hearing loss associated with molecularly confirmed biallelic
Azelaic acid
go.drugbank.com/drugs/DB00548ApprovedInvestigationalAzelaic acid is a saturated dicarboxylic acid found naturally in wheat, rye, and barley. It is also produced by Malassezia furfur, also known as Pityrosporum ovale, which is a species of fungus that is normally found on human skin. Azela...
Categories: Anti-Acne Preparations for Topical UseCryptenamine
go.drugbank.com/drugs/DB00785ApprovedCryptenamine is a mixture of closely related hypotensive alkaloids from Veratrum album (Liliaceae). It has been used in the treatment of hypertension but has largely been replaced by drugs with fewer adverse effects. Cryptenamine has a m...
Esterified estrogens
go.drugbank.com/drugs/DB09381ApprovedIt is being also for the prevention and treatment of osteoporosis.
Repotrectinib
go.drugbank.com/drugs/DB16826ApprovedInvestigational[A262066] On November 15th, 2023, the FDA approved repotrectinib under the brand name Augtyro for the treatment of locally advanced or metastatic ROS1-Positive NSCLC. … [A262056] ROS1 mutations are one of the defined oncogenic drives of NSCLC, and the solvent-front mutation ROS1 G2032R is responsible for 50 to 60% of [crizotinib]-resistant cases.
Neisseria meningitidis group a capsular polysaccharide diphtheria toxoid conjugate antigen
go.drugbank.com/drugs/DB10798ApprovedInvestigationalNeisseria meningitidis group a capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria
Chromium Cr-51
go.drugbank.com/drugs/DB11140ApprovedInvestigationalChromium Cr-51 is an isotope of chromium that has been used as a radioactive label for decades.